Antagonism of LPA1 and LPA2 should attenuate pulmonary fibrosis to a greater extent than an irreversible LPA1 antagonist due to the ability of LPA2 to increase TGF-β levels. This evidence concerns the gene LPAR1 and pulmonary fibrosis.